Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Ingenol mebutate: A novel topical drug for actinic keratosis.

Aditya S, Gupta S.

Indian Dermatol Online J. 2013 Jul;4(3):246-9. doi: 10.4103/2229-5178.115538.

2.

Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.

Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, Katsamas J.

J Am Acad Dermatol. 2009 Jun;60(6):934-43. doi: 10.1016/j.jaad.2009.01.008.

PMID:
19467365
3.

PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.

Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM.

Australas J Dermatol. 2009 Feb;50(1):16-22. doi: 10.1111/j.1440-0960.2008.00497.x.

PMID:
19178487
4.

Ingenol mebutate: a new option for actinic keratosis treatment.

Gras J.

Drugs Today (Barc). 2013 Jan;49(1):15-22. doi: 10.1358/dot.2013.49.1.1910723. Review.

PMID:
23362492
5.

Ingenol mebutate gel for actinic keratosis.

Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B.

N Engl J Med. 2012 Mar 15;366(11):1010-9. doi: 10.1056/NEJMoa1111170.

6.

Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.

Gupta AK, Paquet M.

J Cutan Med Surg. 2013 May-Jun;17(3):173-9. Review.

PMID:
23673300
7.

New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.

Berman B.

Clin Cosmet Investig Dermatol. 2012;5:111-22. doi: 10.2147/CCID.S28905.

8.

Ingenol mebutate gel 0.015% and 0.05%: in actinic keratosis.

Keating GM.

Drugs. 2012 Dec 24;72(18):2397-405. doi: 10.2165/11470090-000000000-00000. Review.

PMID:
23231025
9.

Dermoscopy and Reflectance Confocal Microscopy for Monitoring the Treatment of Actinic Keratosis with Ingenol Mebutate Gel: Report of Two Cases.

Longo C, Borsari S, Benati E, Moscarella E, Alfano R, Argenziano G.

Dermatol Ther (Heidelb). 2016 Mar;6(1):81-7. doi: 10.1007/s13555-016-0094-9.

10.

Ingenol mebutate: an introduction.

Fallen RS, Gooderham M.

Skin Therapy Lett. 2012 Feb;17(2):1-3.

11.

Efficacy, safety and tolerability of field treatment of actinic keratosis with ingenol mebutate 0.015 % gel: a single center case series.

Bobyr I, Campanati A, Consales V, Giuliodori K, Scalise A, Offidani A.

Springerplus. 2016 May 14;5:627. doi: 10.1186/s40064-016-2290-6.

12.

Interventions for actinic keratoses.

Gupta AK, Paquet M, Villanueva E, Brintnell W.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD004415. doi: 10.1002/14651858.CD004415.pub2. Review.

PMID:
23235610
13.
14.

Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.

Berman B.

Expert Opin Drug Saf. 2015;14(12):1969-78. doi: 10.1517/14740338.2015.1108962. Review.

PMID:
26524598
15.

Ingenol mebutate: potential for further development of cancer immunotherapy.

Doan HQ, Gulati N, Levis WR.

J Drugs Dermatol. 2012 Oct;11(10):1156-7.

16.

The paradigm shift in treating actinic keratosis: a comprehensive strategy.

Stockfleth E.

J Drugs Dermatol. 2012 Dec;11(12):1462-7. Review.

PMID:
23377517
17.

Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.

Erlendsson AM, Karmisholt KE, Haak CS, Stender IM, Haedersdal M.

J Am Acad Dermatol. 2016 Apr;74(4):709-15. doi: 10.1016/j.jaad.2015.11.034.

PMID:
26810403
18.

Clinical findings using ingenol mebutate gel to treat actinic keratoses.

Martin G, Swanson N.

J Am Acad Dermatol. 2013 Jan;68(1 Suppl 1):S39-48. doi: 10.1016/j.jaad.2012.09.050.

PMID:
23228305
19.

Ingenol mebutate: a succinct review of a succinct therapy.

Alchin DR.

Dermatol Ther (Heidelb). 2014 Dec;4(2):157-64. doi: 10.1007/s13555-014-0061-2.

20.
Items per page

Supplemental Content

Support Center